Shots:
- Aplagon has dosed the first patient with APAC (IV) in its P-IIa (HEALING) trial in Finland for peripheral arterial occlusive disease (PAOD), leading to chronic limb-threatening ischemia (CLTI)
- Trial will evaluate APAC in ~42 CTLI pts across 4 cohorts to assess safety, efficacy, & effects on thrombo-inflammatory biomarkers. Additionally, an associated PET imaging study with 89Zr-labeled APAC in PAOD is expected to be completed in H1’26
- Aplagon is also planning a P-II trial in 2026 in the EU for Arteriovenous Fistula (AVF) Maturation Failure after a successful P-I AVF study that showed favorable early maturation results with no safety concerns
Ref: Globenewswire | Image: Aplagon | Press Release
Related News: BMS Reports P-II/III (SUCCESSOR-2) Trial Data on Mezigdomide Combination for R/R Multiple Myeloma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
